EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI® OBSERVATIONAL PROGRAMME IN THE UK

被引：2
|
作者：
Hanna, Jerome [1 ]
Rosen, Jan Paul [1 ]
Smethurst, Caroline [1 ]
机构：
[1] Biogen Idec Ltd, Maidenhead, Berks, England
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2013年 / 84卷 / 11期
关键词：
D O I：
10.1136/jnnp-2013-306573.179
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis
    Prosperini, L.
    Mancinelli, C. R.
    Gianni, C.
    Barletta, V.
    Fubelli, F.
    Borriello, G.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 469 - 470
  • [42] Natalizumab: A guide to its use in relapsing-remitting multiple sclerosis
    Keating G.M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2014, 30 (2) : 48 - 54
  • [43] Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia
    Algahtani, Hussein
    Shirah, Bader
    Abobaker, Hind
    Alghanaim, Nebras
    Kamel, Fatemah
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (06) : 199 - 201
  • [44] Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
    Havrdova, Eva
    Galetta, Steven
    Hutchinson, Michael
    Stefoski, Dusan
    Bates, David
    Polman, Chris H.
    O'Connor, Paul W.
    Giovannoni, Gavin
    Phillips, J. Theodore
    Lublin, Fred D.
    Pace, Amy
    Kim, Richard
    Hyde, Robert
    LANCET NEUROLOGY, 2009, 8 (03): : 254 - 260
  • [45] Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients
    Berkovich, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S154 - S155
  • [46] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [47] Efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis in real world clinical practice
    Totaro, R.
    Costantino, G.
    Bellantonio, P.
    Danni, M.
    Di Carmine, C.
    Fantozzi, R.
    Cerqua, R.
    Fuiani, A.
    Mundi, C.
    Ruggieri, S.
    Marini, C.
    Provinciali, L.
    Carolei, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 267 - 267
  • [48] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    CNS DRUGS, 2013, 27 (08) : 591 - 609
  • [49] Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
    Yavari, Fatemeh
    Oliazadeh, Pardis
    Radfar, Meisam
    Foroughipour, Mohsen
    Nikkhah, Karim
    Bakavoli, Alireza Heidari
    Saeidi, Morteza
    BASIC AND CLINICAL NEUROSCIENCE, 2021, 12 (02) : 233 - 242
  • [50] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Jiwon Oh
    Paul W. O’Connor
    CNS Drugs, 2013, 27 : 591 - 609
12345